Hormone receptor positive breast cancer
Not recruitingStudy Comparing Standard Chemotherapy with Letrozole and Abemaciclib for High/Intermediate Risk HR-Positive, HER2-Negative Breast Cancer Patients
Study Comparing Standard Chemotherapy with Letrozole and Abemaciclib for High/Intermediate Risk HR-Positive, HER2-Negative Breast Cancer Patients
- Disease:Hormone receptor positive breast cancer
- Substances:Abemaciclib
Spain- Participants:18–64 years · 65+ years
- Substances:Abemaciclib
- Sponsor:Fundacion Grupo Espanol De Investigacion En Cancer De Mama











